Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies.

Xie, Bailu; Li, Zhengdong; Zhou, Jianfeng; Wang, Wen

Xie, Bailu; Li, Zhengdong; Zhou, Jianfeng; Wang, Wen.

Afiliação

Xie B; IASO Biotherapeutics Co., Ltd., No.77-78, Lane 887, Zuchongzhi Rd, Pudong, Shanghai 200120, China.
Li Z; Department of Breast Surgery, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200020, China.
Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Wang W; IASO Biotherapeutics Co., Ltd., No.77-78, Lane 887, Zuchongzhi Rd, Pudong, Shanghai 200120, China.

Cancers (Basel) ; 14(13)2022 Jun 30.

Article em En | MEDLINE | ID: mdl-35805001

Palavras-chave

antigen escape; bispecific CAR; chimeric antigen receptor T cells; dual-targeting; hematological malignancies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google